Rein Therapeutics, Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Operating Expenses
Income Breakdown
Revenue
$0
R&D↓-39.8% -$1M
$2M
D&A
$0
Operating Income↑+9.5% +$579K
$-5M
EBITDA
$0
Interest Expense
—
Tax Provision
—
Net Income↑+4.5% +$266K
$-6M
Deferred Tax Liabilities
$0
NOL Carryforwards
—
ETR (Continuing Operations)↓-1.0pts
1.4%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-2.5pts
-1.2%
ETR Foreign Differential (pp)↑+0.0pts
0.0%
Operating Lease Cost
—
Income YoY Variation↑+215.7pts
9.5%
Income QoQ Variation↓-12.8pts
20.1%